[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651656":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":11,"studyPopulation":11,"armGroups":36,"interventions":51,"overallOfficials":11,"centralContacts":11,"locations":60,"responsibleParty":245,"collaborators":11,"id":247,"slug":248,"hasResults":249,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":11,"eligibilityCriteria":253,"healthyVolunteers":249,"sex":254,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":11,"studyType":260,"phases":261,"briefSummary":263,"conditions":264,"keywords":11,"overallStatus":266,"whyStopped":11,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":276},{"fullName":5,"class":6},"Assembly Biosciences","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Proportion of subjects with adverse events (AEs), premature treatment discontinuation and abnormal laboratory results.",null,"Through study completion, an average of 1.5 years.",{"measure":14,"description":11,"timeFrame":12},"Evaluating the change from baseline in HDV RNA & ALT levels",[16,18,20,22,24,26,28],{"measure":17,"description":11,"timeFrame":12},"Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AEs and abnormal laboratory results.",{"measure":19,"description":11,"timeFrame":12},"Proportion of participants with undetectable HDV RNA or ≥2 log10 IU\u002FmL reduction in HDV RNA",{"measure":21,"description":11,"timeFrame":12},"In participants with abnormal baseline ALT, the proportion of participants with normal ALT",{"measure":23,"description":11,"timeFrame":12},"Change from baseline in log10 HDV RNA",{"measure":25,"description":11,"timeFrame":12},"In participants with abnormal baseline ALT, the change from baseline in ALT",{"measure":27,"description":11,"timeFrame":12},"In participants with abnormal baseline ALT, proportion of participants with normal ALT",{"measure":29,"description":11,"timeFrame":12},"To characterize the PK of ABI-6250 in plasma in participants with cHDV",{"allocation":31,"interventionModel":32,"interventionModelDescription":11,"primaryPurpose":33,"observationalModel":11,"timePerspective":11,"maskingInfo":34},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":35,"maskingDescription":11,"whoMasked":11},"NONE",[37,42,45,48],{"label":38,"type":39,"description":11,"interventionNames":40},"Treatment Arm 1","EXPERIMENTAL",[41],"Drug: ABI-6250",{"label":43,"type":39,"description":11,"interventionNames":44},"Treatment Arm 2",[41],{"label":46,"type":39,"description":11,"interventionNames":47},"Treatment Arm 3",[41],{"label":49,"type":39,"description":11,"interventionNames":50},"Treatment Arm 4",[41],[52,57],{"type":53,"name":54,"description":55,"armGroupLabels":56,"otherNames":11},"DRUG","ABI-6250","Once daily tablet dosing for 48 weeks starting at Day 1 visit",[38,43,49],{"type":53,"name":54,"description":58,"armGroupLabels":59,"otherNames":11},"Once daily tablet dosing for 48 weeks, starting at Week 16 visit",[46],[61,72,80,88,98,108,116,126,134,144,154,164,169,179,184,189,194,204,214,222,232,237],{"facility":62,"status":11,"city":63,"state":11,"zip":11,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":11},"AP-HP - Beaujon Hospital","Clichy","France","FR",{"type":67,"coordinates":68},"Point",[69,70],2.30952,48.90018,{"lat":70,"lon":69},{"facility":73,"status":11,"city":74,"state":11,"zip":11,"country":64,"countryCode":65,"cosmosGeoPoint":75,"geoPoint":79,"contacts":11},"Hôpital Henri-Mondor","Créteil",{"type":67,"coordinates":76},[77,78],2.46569,48.79266,{"lat":78,"lon":77},{"facility":81,"status":11,"city":82,"state":11,"zip":11,"country":64,"countryCode":65,"cosmosGeoPoint":83,"geoPoint":87,"contacts":11},"CHU Lyon - Hôpital Croix-Rousse","Lyon",{"type":67,"coordinates":84},[85,86],4.84789,45.74906,{"lat":86,"lon":85},{"facility":89,"status":11,"city":90,"state":11,"zip":11,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":11},"LLC Neolab","Tbilisi","Georgia","GE",{"type":67,"coordinates":94},[95,96],44.83412,41.69143,{"lat":96,"lon":95},{"facility":99,"status":11,"city":100,"state":11,"zip":11,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":11},"Universitätsklinikum Hamburg-Eppendorf","Hamburg","Germany","DE",{"type":67,"coordinates":104},[105,106],9.99302,53.55073,{"lat":106,"lon":105},{"facility":109,"status":11,"city":110,"state":11,"zip":11,"country":101,"countryCode":102,"cosmosGeoPoint":111,"geoPoint":115,"contacts":11},"Medizinische Hochschule Hannover","Hanover",{"type":67,"coordinates":112},[113,114],9.73322,52.37052,{"lat":114,"lon":113},{"facility":117,"status":11,"city":118,"state":11,"zip":11,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":11},"Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico","Milan","Italy","IT",{"type":67,"coordinates":122},[123,124],9.18951,45.46427,{"lat":124,"lon":123},{"facility":127,"status":11,"city":128,"state":11,"zip":11,"country":119,"countryCode":120,"cosmosGeoPoint":129,"geoPoint":133,"contacts":11},"Azienda Ospedaliera Universitaria","Naples",{"type":67,"coordinates":130},[131,132],14.26811,40.85216,{"lat":132,"lon":131},{"facility":135,"status":11,"city":136,"state":11,"zip":11,"country":137,"countryCode":138,"cosmosGeoPoint":139,"geoPoint":143,"contacts":11},"Clinical Republican Hospital","Chisinau","Moldova","MD",{"type":67,"coordinates":140},[141,142],28.85938,47.00902,{"lat":142,"lon":141},{"facility":145,"status":11,"city":146,"state":11,"zip":11,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":153,"contacts":11},"New Zealand Clinical Research","Auckland","New Zealand","NZ",{"type":67,"coordinates":150},[151,152],174.76349,-36.84853,{"lat":152,"lon":151},{"facility":155,"status":11,"city":156,"state":11,"zip":11,"country":157,"countryCode":158,"cosmosGeoPoint":159,"geoPoint":163,"contacts":11},"Aga Khan University Hospital","Karachi","Pakistan","PK",{"type":67,"coordinates":160},[161,162],67.0104,24.8608,{"lat":162,"lon":161},{"facility":165,"status":11,"city":156,"state":11,"zip":11,"country":157,"countryCode":158,"cosmosGeoPoint":166,"geoPoint":168,"contacts":11},"Dr. Ziauddin Hospital",{"type":67,"coordinates":167},[161,162],{"lat":162,"lon":161},{"facility":170,"status":11,"city":171,"state":11,"zip":11,"country":172,"countryCode":173,"cosmosGeoPoint":174,"geoPoint":178,"contacts":11},"Arensia Research Clinic","Bucharest","Romania","RO",{"type":67,"coordinates":175},[176,177],26.10626,44.43225,{"lat":177,"lon":176},{"facility":180,"status":11,"city":171,"state":11,"zip":11,"country":172,"countryCode":173,"cosmosGeoPoint":181,"geoPoint":183,"contacts":11},"Dr. Victor Babes Foundation",{"type":67,"coordinates":182},[176,177],{"lat":177,"lon":176},{"facility":185,"status":11,"city":171,"state":11,"zip":11,"country":172,"countryCode":173,"cosmosGeoPoint":186,"geoPoint":188,"contacts":11},"Fundeni Clinical Institute",{"type":67,"coordinates":187},[176,177],{"lat":177,"lon":176},{"facility":190,"status":11,"city":171,"state":11,"zip":11,"country":172,"countryCode":173,"cosmosGeoPoint":191,"geoPoint":193,"contacts":11},"Prof. Dr. Matei Bals National Institute of Infectious Diseases",{"type":67,"coordinates":192},[176,177],{"lat":177,"lon":176},{"facility":195,"status":11,"city":196,"state":11,"zip":11,"country":197,"countryCode":198,"cosmosGeoPoint":199,"geoPoint":203,"contacts":11},"Hospital Clínico Universitario Lozano Blesa","Zaragoza","Spain","ES",{"type":67,"coordinates":200},[201,202],-0.87734,41.65606,{"lat":202,"lon":201},{"facility":205,"status":11,"city":206,"state":11,"zip":11,"country":207,"countryCode":208,"cosmosGeoPoint":209,"geoPoint":213,"contacts":11},"ARENSIA Exploratory Medicine Ivano-Frankivsk","Ivano-Frankivsk","Ukraine","UA",{"type":67,"coordinates":210},[211,212],24.71248,48.92312,{"lat":212,"lon":211},{"facility":215,"status":11,"city":216,"state":11,"zip":11,"country":207,"countryCode":208,"cosmosGeoPoint":217,"geoPoint":221,"contacts":11},"Medical Center of LLC ARENSIA Exploratory Medicine","Kyiv",{"type":67,"coordinates":218},[219,220],30.5238,50.45466,{"lat":220,"lon":219},{"facility":223,"status":11,"city":224,"state":11,"zip":11,"country":225,"countryCode":226,"cosmosGeoPoint":227,"geoPoint":231,"contacts":11},"King's College Hospital London","London","United Kingdom","UK",{"type":67,"coordinates":228},[229,230],-0.12574,51.50853,{"lat":230,"lon":229},{"facility":233,"status":11,"city":224,"state":11,"zip":11,"country":225,"countryCode":226,"cosmosGeoPoint":234,"geoPoint":236,"contacts":11},"The Royal London Hospital",{"type":67,"coordinates":235},[229,230],{"lat":230,"lon":229},{"facility":238,"status":11,"city":239,"state":11,"zip":11,"country":225,"countryCode":226,"cosmosGeoPoint":240,"geoPoint":244,"contacts":11},"North Manchester General Hospital","Manchester",{"type":67,"coordinates":241},[242,243],-2.23743,53.48095,{"lat":243,"lon":242},{"type":246,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100651656","phase-2-a-study-to-assess-the-safety-pharmacokinetics-and-efficacy-of-abi-6250-in-participants-with-chronic-hepatitis-d-virus-infection-100651656",false,"NCT07762027","A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection","A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection","Inclusion Criteria:\n\n* Participant has a body mass index ≥18.0 and \\\u003C35.0 kg\u002Fm2 at Screening\n* Other than HBV and HDV infection, the participant is in good health (as determined by the Investigator) based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory results.\n* Participant agrees to comply with protocol-specified contraception requirements.\n\nExclusion Criteria:\n\n* Participant has a current coinfection with acute hepatitis A virus (HAV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).\n* Participant has a history of any significant food or drug-related allergic reactions such as anaphylaxis, Stevens-Johnson syndrome, or urticaria.\n* Participant has been treated for HDV infection in the past 6 months prior to Day 1.\n* Participant took part in another clinical trial of a drug or device (other than for HDV infection) whereby the last study drug\u002Fdevice administration is within 30 days or 5 half-lives, whichever is longer, prior to Day 1.","ALL","18 Years","70 Years",{"count":258,"type":259},80,"ESTIMATED","INTERVENTIONAL",[262],"PHASE2","This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.",[265],"Chronic Hepatitis D Infection","NOT_YET_RECRUITING","2026-08-07",{"date":269,"type":270},"2026-08-13","ACTUAL",{"date":272,"type":259},"2026-10",{"date":274,"type":259},"2028-09",{"name":5,"class":6},22]